Method for preparing clinical-grade mixed immune cells

By isolating mononuclear cells from peripheral blood and cultured with specific culture medium, a mixed immune cell population of CD3-CD56+ and CD3+CD56+ was prepared, which solved the problem of insufficient combined application of immune cells in the prior art and achieved efficient The killing effect of tumor cells provides new treatment options for tumor patients.

CN115505567BActive Publication Date: 2024-11-22JILIN TUOHUA PHARMACEUTICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211172103.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-26
Publication Date
2024-11-22
Estimated Expiration
2042-09-26

AI Technical Summary

Technical Problem

In the prior art, most of the immune cells used in clinical practice are CIK or NK alone, and the combined application is less, and there is no report on the killing function of tumor cells. How to design a one-time preparation containing CD3-CD56+ and CD3 The +CD56+ lymphocyte method is an urgent problem to be solved.

Method used

Provide a clinical-grade mixed immune cell preparation method, by isolating mononuclear cells from peripheral blood, cultured using specific complete medium A, B and C, and CD3-CD56+ is obtained during 16 days of culture. It is a mixed immune cell population with CD3+CD56+, which is a major effector cell, and is named MAK cells.

Benefits of technology

Simple preparation process, stable active ingredients, high cytotoxicity and low cost, making up for the combination of multiple immune cells, providing a new treatment plan for tumor patients and sub-healthy patients. MAK cells have a broad spectrum of tumor cells. Destructive effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115505567B_ABST
    Figure CN115505567B_ABST
Patent Text Reader

Abstract

The present invention discloses a method for preparing a clinical-grade mixed immune cell, and the steps include: using lymphocyte separation fluid to separate mononuclear cells from peripheral blood; complete culture medium A liquid suspends mononuclear cells, and after mixing, is placed in an incubator for culture; after culture, an equal volume of complete culture medium B liquid is added to the culture fluid, and after mixing, it is placed in an incubator for continued culture; every 2 to 3 days, according to the cell counting result, an equal volume of complete culture medium C liquid is supplemented; after 16 days of culture, a mixed immune cell group with CD3-CD56+, CD3+CD56+ as the main effector cells is obtained. The technical solution of the present invention can provide a mixed immune cell containing NK and CIK, which is a large number of immune cell groups with multiple immune activities obtained by in vitro induction and amplification culture of mononuclear cells, including CD3-CD56+ cell group, CD3+CD56+ cell group. Its preparation process is simple, the effective ingredients are stable, the cytotoxicity is high, and the cost is low, which makes up for the vacancy of multiple immune cell combined therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a method for preparing clinical-grade mixed immune cells. Background Art

[0002] Cell therapy is another tumor treatment method after surgery, radiotherapy and chemotherapy. It is generally used as an auxiliary means of surgery, radiotherapy and chemotherapy to prolong the patient's life and remove residual cancer cells in the body after surgery. Commonly used immune cells include cytokine-induced killer cells (CIK), natural killer cells (NK), dendritic cells (DC), lymphokine-activated killer cells (LAK), tumor infiltrating lymphocytes (TIL), etc.

[0003] CIK and NK cells are two important parts of tumor immunotherapy. CIK is a group of cells with strong anti-tumor activity of T lymphocytes and non-major histocompatibility complex restricted cells of NK cells, and CD3+CD56+ cells are its main effector cells. CIK cells mainly kill target cells in an MHC-restricted manner, and DC cells present antigens to CIK cells in an MHC-restricted manner to activate the killing effect of CIK cells, eliminate residual tumor cells and play a more powerful cytotoxic effect. NK cells are a group of lymphocytes expressing CD3-CD56+. NK cells have no MHC restriction in recognizing tumors and viruses, are not dependent on antibodies, and can play the role of killing tumors and viruses without sensitization. NK cells are also the first line of defense against tumors and infections. NK cells can also secrete a variety of cytokines, such as perforin, cytotoxic factors, TNF, IFN-y, IL-2, etc. to play an immune surveillance function. CIK cells can specifically kill tumor cells, but cannot recognize tumor cells that do not express MHC-I molecules, while NK cells can recognize tumor cells that do not express MHC-I molecules and kill them. Therefore, the co-infusion of the two can effectively kill most tumor cells.

[0004] A large number of clinical studies have shown that CIK and NK have the effects of improving the clinical cure rate of tumors, reducing tumor recurrence, improving the quality of life, and prolonging survival. At present, the technologies for inducing CIK and NK in vitro are relatively mature, and cells that meet clinical use can be obtained. However, most of the cells used in clinical practice are CIK or NK alone, and there are fewer combined applications for treatment, and there is a lack of reports on the killing function of combined applications on tumor cells. Zhang Guanghui, Shao Xiaoyan and others have shown that the combined use of CIK and NK cells has better killing toxicity to tumor cells than using them alone.

[0005] In summary, how to design a method for preparing lymphocytes containing CD3-CD56+ and CD3+CD56+ at one time is a problem that needs to be solved urgently by those skilled in the art. Summary of the invention

[0006] The main purpose of the embodiment of the present invention is to provide a method for preparing clinical-grade mixed immune cells, aiming to prepare lymphocytes containing CD3-CD56+ and CD3+CD56+ at one time.

[0007] The technical solution of the present invention to solve the above technical problems is to provide a method for preparing clinical-grade mixed immune cells, the steps of which include:

[0008] Mononuclear cells were isolated from peripheral blood using lymphocyte separation medium;

[0009] Suspend the mononuclear cells in complete medium A, mix well, and culture in an incubator;

[0010] After the culture, add an equal volume of complete medium B to the culture solution, mix well, and place in the incubator to continue the culture;

[0011] Complete medium C was supplemented in equal volumes every 2 to 3 days based on the cell count results;

[0012] After 16 days of culture, a mixed immune cell population with CD3-CD56+ and CD3+CD56+ as the main effector cells was obtained.

[0013] In one embodiment of the present invention, the complete culture medium A solution comprises: SCGM NK culture medium containing 1ug / ml to 5ug / ml CD16 monoclonal antibody, 20ug / ml to 100μg / ml of Lipofectamine and 2% to 5% serum replacement.

[0014] In one embodiment of the present invention, the complete culture medium B solution includes: 10ug / ml to 100ug / ml thymus alpha-sin, 1000ug / ml to 5000U / ml IL-2, 10ug / ml to 100ng / ml IL15 and 2% to 5% serum replacement.

[0015] In one embodiment of the present invention, the complete culture medium C solution comprises: 1% to 3% serum replacement, 1000U / ml to 2000U / ml IL-2 and 1U / ml to 10ug / ml LacNAC.

[0016] In one embodiment of the present invention, the step of separating mononuclear cells from peripheral blood using a lymphocyte separation solution comprises:

[0017] Peripheral blood was placed in a 50 ml centrifuge tube and placed in a centrifuge;

[0018] Add an equal volume of hydroxyethyl starch injection, shake well and place in a centrifuge with a centrifugal force of 250 g for 20 minutes;

[0019] The supernatant was discarded, and an equal volume of PBS was added to the cell pellet, mixed, and then lymphocyte separation solution was added and centrifuged at 800 g;

[0020] Collect the buffy coat layers in a new centrifuge tube, add PBS to the centrifuge tube containing PBMC, mix well, put into a centrifuge, centrifuge at a centrifugal force of 400g, centrifuge and wash for 10 minutes, centrifuge and wash twice to obtain mononuclear cells.

[0021] In one embodiment of the present invention, the steps of suspending mononuclear cells in complete medium A, mixing, and placing in an incubator for culture include:

[0022] Suspend the mononuclear cells in complete medium A, mix well, and adjust the cell concentration to 1×10 6 ~2×10 6 cells / ml;

[0023] After adjustment, place in an incubator for culture.

[0024] In one embodiment of the present invention, in the step of replenishing the complete medium C solution in equal volume every 2 to 3 days according to the cell counting results, the cell density is maintained at 1×10 6 ~3×10 6 cells / ml.

[0025] The technical solution of the present invention provides a mixed immune cell containing NK and CIK, named MAK (Mixed-activated killer) immune cell, which is a large number of immune cell groups with multiple immune activities obtained by in vitro induction and amplification of mononuclear cells, including CD3-CD56+ cell group and CD3+CD56+ cell group. It has the characteristics of simple preparation process, stable effective ingredients, high cytotoxicity and low cost, which makes up for the vacancy of combined treatment of multiple immune cells and provides a new treatment plan for tumor patients and sub-health patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the structures shown in these drawings without paying creative work.

[0027] Figure 1This is a schematic diagram of the process of preparing clinical-grade mixed immune cells according to the present invention;

[0028] Figure 2 This is a schematic flow chart of step S10 of the method for preparing clinical-grade mixed immune cells of the present invention;

[0029] Figure 3 This is a schematic flow chart of step S20 of the method for preparing clinical-grade mixed immune cells of the present invention;

[0030] Figure 4 The flow cytometry phenotype diagram of MAK in the method for preparing clinical-grade mixed immune cells of the present invention;

[0031] Figure 5 This is one of the MAK killing toxicity detection diagrams of the method for preparing clinical-grade mixed immune cells of the present invention;

[0032] Figure 6 This is one of the MAK killing toxicity detection diagrams of the method for preparing clinical-grade mixed immune cells of the present invention;

[0033] Figure 7 This is the flow cytometry phenotype diagram of MAK, CIK and NK in the method for preparing clinical-grade mixed immune cells described in the present invention. DETAILED DESCRIPTION

[0034] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0035] It should be noted that all directional indications in the embodiments of the present invention (such as up, down, left, right, front, back, etc.) are only used to explain the relative position relationship, movement status, etc. between the components under a certain specific posture (as shown in the accompanying drawings). If the specific posture changes, the directional indication will also change accordingly.

[0036] In addition, in the present invention, descriptions such as "first", "second", etc. are only used for descriptive purposes and cannot be understood as indicating or implying their relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" or "second" may explicitly or implicitly include at least one of the features. In the description of the present invention, the meaning of "several" or "multiple" is at least two, such as two, three, etc., unless otherwise clearly and specifically defined.

[0037] In the present invention, unless otherwise clearly specified and limited, the terms "connection", "fixation", etc. should be understood in a broad sense. For example, "fixation" can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection or an indirect connection through an intermediate medium, it can be the internal connection of two elements or the interaction relationship between two elements, unless otherwise clearly defined. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.

[0038] In addition, the technical solutions between the various embodiments of the present invention can be combined with each other, but it must be based on the fact that ordinary technicians in the field can implement it. When the combination of technical solutions is contradictory or cannot be implemented, it should be deemed that such combination of technical solutions does not exist and is not within the scope of protection required by the present invention.

[0039] The present invention provides a method for preparing clinical-grade mixed immune cells, aiming to prepare lymphocytes containing CD3-CD56+ and CD3+CD56+ at one time.

[0040] The specific structure of the method for preparing clinical-grade mixed immune cells proposed by the present invention will be described in the following specific examples:

[0041] In the technical solution of this embodiment, Figure 1 As shown, a method for preparing clinical-grade mixed immune cells comprises the following steps:

[0042] S10: Mononuclear cells were isolated from peripheral blood using lymphocyte separation medium;

[0043] S20: Suspend mononuclear cells in complete medium A, mix well, and culture in an incubator;

[0044] It can be understood that complete medium A can activate NK cells, enhance their activity and cytotoxicity, and eliminate possible remaining tumor cells, allowing NK cells, CIK cells, and progenitor cells to survive preferentially.

[0045] S30: After the culture, add an equal volume of complete medium B to the culture solution, mix well, and continue to culture in an incubator;

[0046] It can be understood that complete medium B can enhance the aggregation and cluster growth of target cells, activate the expression of activation receptors on their surfaces, and enhance their activity and cytotoxicity.

[0047] S40: replenish complete medium C in equal volume every 2 to 3 days based on cell count results;

[0048] Understandably, complete medium C can provide sufficient nutrients for cell proliferation, while improving antioxidant and activity, and inhibiting the proliferation of non-target cells;

[0049] S50: After 16 days of culture, a mixed immune cell population with CD3-CD56+ and CD3+CD56+ as the main effector cells was obtained.

[0050] Understandably, the present invention provides a mixed immune cell containing NK and CIK, named MAK (Mixed-activated killer) immune cell, which is a large number of immune cell groups with multiple immune activities obtained by in vitro induction and amplification culture of mononuclear cells, including CD3-CD56+ cell group and CD3+CD56+ cell group. It has the characteristics of simple preparation process, stable effective ingredients, high cytotoxicity and low cost, which makes up for the vacancy of combined treatment of multiple immune cells and provides a new treatment plan for tumor patients and sub-health patients.

[0051] In one embodiment of the present invention, the complete culture medium A solution comprises: SCGM NK culture medium containing 1 μg / ml to 5 ug / ml CD16 monoclonal antibody, 20 μg / ml to 100 μg / ml of Lipofectamine and 2% to 5% serum replacement.

[0052] Understandably, CD16 monoclonal antibodies are beneficial to the activation and expansion of NK cells, activating the antibody-dependent cell-mediated cytotoxicity of NK cells, and can significantly increase the number of NK expansion; SCGM NK culture medium is an optimized xeno-free GMP culture medium, which is very beneficial to the culture of NK cells and CIK cells, and can ensure the dominant growth of NK and CIK. It can also be used for serum-free expansion of a small amount of isolated human hematopoietic stem cells and progenitor cells, ensuring the survival of progenitor cells and their differentiation into NK. GT-551H3 serum-free culture medium is a conventional serum-free culture medium suitable for the culture of human lymphocytes, DC cells, and NK cells, and suitable for later large-scale culture. The combined application of multiple culture media can achieve the advantageous growth and component stability of the target cells under the premise of saving costs; Lierfan can effectively induce the body to produce IL-2 and tumor necrosis factor, and activate macrophages and NK cells; secondly, Lierfan kills tumor cells by destroying their DNA, and has a strong killing and inhibitory effect on primary and transplanted tumors, and eliminates tumor cells that may remain in PBMC; serum substitutes are synthetic cell nutritional factors that can replace the patient's own plasma in the cell culture process, avoiding the shortcomings of poor plasma quality and deficiency, and can stabilize the culture process and production capacity.

[0053] In one embodiment of the present invention, the complete culture medium B solution includes: 10 μg / ml to 100 ug / ml thymus alpha-sin, 1000 μg / ml to 5000 U / ml IL-2, 10 μg / ml to 100 ng / ml IL15 and 2% to 5% serum replacement.

[0054] Understandably, thymosin can enhance the aggregation of NK cells and their cytotoxicity. At the same time, it increases the secretion level of interleukin 2; IL-2 / IL-15 are cytokines with similar structures, which can effectively regulate the activation and proliferation of T cells and NK cells. IL-2 is a necessary stimulating factor for immune cell culture. Cells lacking IL-2 shrink and apoptosis; serum substitutes are synthetic cell nutrition factors that can replace the patient's own plasma in the cell culture process, avoiding the shortcomings of poor quality and insufficient plasma, and can stabilize the culture process and production capacity.

[0055] In one embodiment of the present invention, the complete culture medium C comprises: 1% to 3% serum replacement, 1000 μg / ml to 2000 U / ml IL-2 and 1 μg / ml to 10 ug / ml LacNAC.

[0056] It can be understood that serum substitutes are synthetic cell nutritional factors that can replace the patient's own plasma during the cell culture process, avoiding the shortcomings of poor plasma quality and insufficiency, and can stabilize the culture process and production capacity; IL-2 has a cytokine with a similar structure and can effectively regulate the activation and proliferation of T cells and NK cells. IL-2 is an essential stimulatory factor for immune cell culture. Cells lacking IL-2 shrink and apoptosis; LacNAC can promote the proliferation of CD3+CD56+ cells, reduce the proliferation of CD3+CD4+ cells, promote the proliferation of CD3+CD8+ cells, and at the same time enhance the antioxidant capacity of immune cell populations and improve their activity.

[0057] In one embodiment of the present invention, Figure 2 As shown, the step of separating mononuclear cells from peripheral blood using lymphocyte separation fluid comprises:

[0058] S11: Peripheral blood is placed in a 50 ml centrifuge tube and placed in a centrifuge;

[0059] It can be understood that the centrifugal conditions of the centrifuge are: the rotation speed is 2000 rpm, the centrifugal time is 10 minutes, and after stratification, the blood cell sediment of the lower layer is taken out;

[0060] S12: Add an equal volume of hydroxyethyl starch injection, shake well and place in a centrifuge with a centrifugal force of 250 g for 20 min;

[0061] S13: discard the supernatant, add an equal volume of PBS to the cell pellet, mix well, add lymphocyte separation solution, and centrifuge at 800g;

[0062] Understandably, after centrifugation for 20 min,

[0063] S14: Collect the buffy coat layers in a new centrifuge tube, add PBS to the centrifuge tube containing PBMC, mix well, put into a centrifuge, centrifuge at a centrifugal force of 400g, centrifuge and wash for 10 minutes, centrifuge and wash twice to obtain mononuclear cells.

[0064] In one embodiment of the present invention, Figure 3 As shown, the steps of suspending mononuclear cells in complete medium A, mixing them, and then culturing them in an incubator include:

[0065] S21: Suspend the mononuclear cells in complete medium A, mix well, and adjust the cell concentration to 1×10 6 ~2×10 6 cells / ml;

[0066] S22: After adjustment, place in an incubator for cultivation.

[0067] In one embodiment of the present invention, in the step of replenishing the complete medium C solution in equal volume every 2 to 3 days according to the cell counting results, the cell density is maintained at 1×10 6 ~3×10 6 cells / ml.

[0068] Embodiment 1 of the present invention

[0069] MAK cell culture:

[0070] The peripheral blood was placed in a 50 ml centrifuge tube and put into a centrifuge. The centrifugal conditions of the centrifuge were: rotation speed of 2000 rpm, centrifugation time of 10 min. After stratification, the blood cell sediment of the lower layer was taken out.

[0071] Add an equal volume of hydroxyethyl starch injection, shake well and place in a centrifuge with a centrifugal force of 250 g for 20 minutes;

[0072] The supernatant was discarded, and an equal volume of PBS was added to the cell pellet, mixed, and then the lymphocyte separation solution was added, and centrifuged at 800 g for 20 min;

[0073] Collect the buffy coat layers in a new centrifuge tube, add PBS to the centrifuge tube containing PBMC, mix well, put into a centrifuge, centrifuge at a centrifugal force of 400g, centrifuge for 10 minutes, and centrifuge twice.

[0074] Suspend mononuclear cells in complete medium A, count, and inoculate at a density of 2.0*106 / ml, mix well and culture in an incubator for 3 days. No observation or rehydration is required for these three days.

[0075] After 3 days, add an equal volume of complete medium B to the culture medium, mix well and continue culturing in the incubator. When the total volume of the culture medium exceeds 200 ml, transfer to a cell culture bag for culturing;

[0076] Every 2 to 3 days, add an equal volume of complete medium C according to the cell count results to maintain the cell density at 1.5 to 2*10 6 / ml;

[0077] After 16 days of culture, a mixed immune cell population with CD3-CD56+ and CD3+CD56+ as the main effector cells was obtained.

[0078] MAK prepared in Example 1: MAK flow cytometry phenotypic detection:

[0079] Collect 2 ml of MAK cell suspension cultured for 16 days, centrifuge at 2000 rpm for 10 min, remove the supernatant, wash the cells twice with PBS, count, and divide into 5 tubes for testing, 5*10 5 / tube, 200ul / tube. ①Blank tube, ②Negative control tube, ③CD3FITC / CD19PE, ④CD3FITC / CD4PE, ⑤CD3FITC / CD8PE / CD56APC, add detection antibodies to the five detection tubes in turn, mix well, keep at room temperature and away from light for 30 minutes, add PBS to wash twice, discard the supernatant, add 500ulPBS to suspend, mix well, and detect the expression of each cell group by flow cytometry.

[0080] like Figure 4 As shown, the MAK cell population is mainly composed of CD3-CD56+ and CD3+CD56+ (CD3+CD8+CD56+) cells, contains a small amount of CD3+CD4<5%, and does not contain other cell populations.

[0081] MAK prepared in Example 1: MAK broad-spectrum killing toxicity test:

[0082] Eleven luciferase-labeled tumor cells were collected in the logarithmic growth phase, washed twice with PBS, and the cell density was adjusted to 6*10 4 / ml, added to 96-well plates, and MAK immune cells were collected at the ratio of effector to target of 10:1 and 5:1, washed twice with PBS, counted, and the cell density was adjusted to 6*10 5 / ml and 3*10 5 / ml, added to 96-well plates, incubated with tumor cells for 24 hours, added detection solution, and carried out killing toxicity detection on chemiluminescence microwell detector;

[0083] Table 1 The killing effect of MAK on different tumor cells

[0084] 10:1 5:1 Bel7402-luc 93.84±3.52a 91.22±4.31a MCF-7-luc 96.12±4.29a 91.07±5.76a NCI-H446-luc 85.96±4.90a 74.94±4.69a 769-P-luc 88.60±8.46a 78.31±10.97a MKN45-luc 96.04±4.95a 90.41±6.49a QGY-7701-luc 90.16±8.02a 84.09±8.32a GBC-SD-luc 26.01±5.52c 11.17±3.76c QBC939-luc 85.19±12.18a 79.02±13.76a HUH7-luc 89.80±6.96a 83.36±12.33a A549 / t-luc 46.64±20.01b 27.55±16.91b HepG2-luc 96.91±4.92a 94.88±6.43a

[0085] From Table 1 and Figure 5 , Figure 6 As shown, MAK has a broad-spectrum killing effect on tumor cells, and exhibits strong killing toxicity to various tumors. It has the highest killing toxicity to liver cancer cells HepG2, and is slightly less sensitive to human non-small cell lung cancer A549 and human gallbladder cancer cells GBC.

[0086] The activity of MAK prepared in Example 1 was compared with CIK and NK respectively:

[0087] Three healthy peripheral blood samples were collected for MAK, CIK, and NK cell culture respectively. After 16 days of culture, flow cytometry phenotyping, enzyme-linked immunosorbent assay for IFN-r secretion capacity, and HepG2-luc cytotoxicity test using different effector targets of immune cells were performed.

[0088] Table 2 Comparison of cell phenotypes, cytokines, and cytotoxicity of MAK, CIK, and NK (CD3-CD19+, CD3+CD4+, CD3+CD8+, CD3-CD56+, and CD3+CD56+ are cell phenotype comparison columns, IFN-r is a cytokine comparison column, and 10:1 and 5: are cytotoxicity comparison columns)

[0089]

[0090]

[0091] From Table 2 and Figure 7 The results showed that there were significant differences among MAK, CIK and NK cell populations. CIK highly expressed CD3+CD56+, NK highly expressed CD3-CD56+, CIK highly expressed CD3-CD56+ and CD3+CD56+. There were significant differences among each subpopulation, P<0.05; there were significant differences in IFN-r secretion ability, MAK>NK>CIK, P<0.05; there were significant differences in cytotoxicity, MAK>NK>CIK, P<0.05.

[0092] The above is only a preferred specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed by the present invention should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.

Claims

1. A method for preparing clinical-grade mixed immune cells, It is characterized in that The steps include: Mononuclear cells were isolated from peripheral blood using lymphocyte separation medium; Suspend the mononuclear cells in complete medium A, mix well, and culture in an incubator; After the culture, add an equal volume of complete medium B to the culture solution, mix well, and place in the incubator to continue the culture; Complete medium C was supplemented in equal volumes every 2 to 3 days based on the cell count results; After 16 days of culture, a mixed immune cell population with CD3-CD56+ and CD3+CD56+ as the main effector cells was obtained; The complete culture medium A solution is composed of SCGM NK culture medium containing 1 μg / ml~5ug / ml CD16 monoclonal antibody, 20 μg / ml~100 μg / ml of Lipofol and 2%~5% serum replacement; The complete culture medium B solution includes: 10 μg / ml~100ug / ml thymus alpha-sin, 1000 μg / ml~5000U / ml IL-2, 10 μg / ml~100ng / ml IL15 and 2%~5% serum replacement; The complete culture medium C solution includes: 1% to 3% serum replacement, 1000 μg / ml to 2000 U / ml IL-2 and 1 μg / ml to 10 ug / ml LacNAC.

2. The method for preparing clinical-grade mixed immune cells according to claim 1, It is characterized in that The step of separating mononuclear cells from peripheral blood using lymphocyte separation fluid comprises: Peripheral blood was placed in a 50 ml centrifuge tube and placed in a centrifuge; Add an equal volume of hydroxyethyl starch injection, shake well and place in a centrifuge with a centrifugal force of 250 g for 20 minutes; The supernatant was discarded, and an equal volume of PBS was added to the cell pellet, mixed, and lymphocyte separation solution was added, and the centrifugal force was 800 g for centrifugation; Collect the buffy coat layer in a new centrifuge tube, add PBS to the centrifuge tube containing PBMC, mix well, put into a centrifuge, centrifuge at a centrifugal force of 400g, centrifuge and wash for 10 minutes, centrifuge and wash twice to obtain mononuclear cells.

3. The method for preparing clinical-grade mixed immune cells according to claim 1, It is characterized in that The steps of suspending the mononuclear cells in complete medium A, mixing them, and then placing them in an incubator for culture include: Suspend the mononuclear cells in complete medium A, mix well, and adjust the cell concentration to 1×10 6 ~2×10 6 cells / ml; After adjustment, place in an incubator for culture.

4. The method for preparing clinical-grade mixed immune cells according to claim 1, It is characterized in that In the step of replenishing the complete medium C solution in equal volume every 2 to 3 days according to the cell counting results, the cell density was maintained at 1×10 6 ~3×10 6 cells / ml.